Skip to main content
OpenTrials
Completed

NCT Number: NCT04722055

A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China

According to data from Global Cancer Statistics 2018, colorectal cancer (CRC) ranks second in incidence and fifth in mortality among all cancers in China. The underlying neoplastic progression from adenoma to CRC endures up to 10 years, providing an extended window for CRC detection and screening. Currently, fecal occult blood test (FOBT) and colonoscopy are the main diagnostic and screening methods for CRC in Chinese clinical practice. However, due to low patients' compliance with colonoscopy and poor sensitivity of FOBT, a large proportion of CRC could not be effectively diagnosed and treated at early stage. Therefore, noninvasive fecal DNA detection approach with enhanced performance is urgently needed in clinic.

The aim of this trial is to evaluate effectiveness of the Human Multigene Methylation Detection Kit (Fluorescent PCR) for auxiliary diagnosis of colorectal cancer. By assessing the level of DNA methylation of certain genes in human stool, the test can indicate whether cancerous and precancerous lesions exist in the areas of colon and rectum.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Advanced Adenocarcinoma Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasm Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Hyperplastic Polyp Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

40 year–79 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Shandong Cancer Hospital and Institute

Jinan, Shandong, China

About this study

The multicenter clinical trial will be conducted using a single-blind method. Stool samples provided by participants will be evaluated by Human Multigene Methylation Detection Kit (Fluorescent PCR). The kit will be used to qualitatively detect methylation levels of multiple genes in human stool samples in vitro by using Quantitative Methylation Specific PCR (qMSP). The principle of the method is as follows. First, the target DNA in human stool is extracted by magnetic bead-capture technology and then treated with sodium bisulfite. The sequence of unmethylated DNA will be changed while that of the methylated DNA remains the same after sodium bisulfite treatment. Subsequently, qMSP is employed to detect methylation levels of target genes in addition to ACTB gene (a reference gene). Controls of ACTB gene with and without methylation are tested simultaneously. Result of qMSP is dichotomized as positive and negative based on Ct value obtained. The test result is then verified by Sanger sequencing and compared with that from colonoscopy examination and pathology report. The main evaluation indexes for test performance are sensitivity, specificity, consistency rate, kappa coefficient.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must also meet the following three criteria to be included in this study:
  • To be 40 to 79 years old, regardless of gender;
  • To participate voluntarily and sign Informed Consent Form;
  • To satisfy any of the following three conditions:
  • Patients with colorectal cancer confirmed or suspected by colonoscopy or pathological biopsy;
  • Patients with gastrointestinal disease or normal population to be examined by colonoscopy;
  • Patients who are planning to undergo colonoscopy or have colonoscopy results from other interfering diseases.

Exclusion criteria

  • Patients with any of the following conditions shall be excluded:
  • To have had radical resection of colorectal cancer before enrollment in this study;
  • To have been deemed ineligible to participate in the study by the principal investigator due to various other reasons.

Treatment and study plan

Multigene Methylation Detection Kit

Diagnostic Test

Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).

Other names: Colosafe 2.0

Primary outcomes

  1. Sensitivity

    Time frame: Two years

    Sensitivity is the true positive fraction of participants with colorectal cancer.

  2. Specificity

    Time frame: Two years

    Specificity is the true negative fraction of participants without colorectal cancer.

  3. Consistency rate

    Time frame: Two years

    Consistency rate is the fraction of both true positive and negative diagnostic test results among all participants.

  4. Kappa coefficient

    Time frame: Two years

    Kappa coefficient is the consistency analysis of the extent of agreement between the test results of Colosafe 2.0 and reference colonoscopy.

Sponsors and collaborators

Lead sponsor

Creative Biosciences (Guangzhou) Co., Ltd.

Industry

Registry information

Official study title

A Multicenter Clinical Trial of Human Multigene Methylation Detection Kit (Fluorescent PCR)

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 25, 2021
Registry last updated
Oct 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.